Results 101 to 110 of about 43,753 (252)

Real-world data in patients with BRCA mutated breast cancer treated with poly (ADP-ribose) polymerase inhibitors. [PDF]

Ecancermedicalscience, 2023
Beas-Lozano EL, Verduzco-Aguirre HC, Gonzalez-Salazar R, Chavarri-Guerra Y.   +3 more
europepmc   +1 more source

CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib

British Journal of Haematology, EarlyView.
Summary Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood.
Omar Faruq, Deepak Iyer, Patrick Wang, Mariusz Shrestha, Cuihong Wei, Aaron D. Schimmer, Hong Chang   +6 more
wiley   +1 more source

Poly (ADP Ribose) Polymerase Inhibitors for Cancer [PDF]

The Journal of Molecular Diagnostics, 2020
Lynette M. Sholl, Diana Mandelker, Tracy Stockley   +2 more
openaire   +1 more source

Ablative radiotherapy in castration‐resistant prostate cancer

BJU International, EarlyView.
Objective To prove the oncological benefit of ablative radiotherapy in patients with up to five metastases from castration‐resistant prostate cancer (CRPC) a single‐centre randomised trial was initiated. Patients and Methods This monocentric, randomised, phase II clinical trial enrolled patients with up to five prostate‐specific membrane antigen ...
Tobias Hölscher, Fabian Lohaus, Lydia Koi, Jörg Kotzerke, Sebastian Hoberück, Christian Thomas, Angelika Borkowetz, Steffen Löck, Mechthild Krause, Esther G.C. Troost   +9 more
wiley   +1 more source

Mapping the Radiopharmaceutical Therapy Landscape for Prostate Cancer: Insights Into Global Clinical Trial Trends and Future Directions

Med Research, EarlyView.
Zhiwu Dong, Sixiang Yan, Xiaodong Liu, Peng Gu   +3 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Synthesis, Characterization, and in vitro Experiments of Saturated Cannabinoids on Pancreatic Ductal Adenocarcinoma Cell Lines (HPAF-II, MIA-PaCa2, ASPC-1, and PANC-1)

Natural Product Communications
Introduction Cannabinoid receptors CB1 and CB2 are the primary endogenous receptors with which cannabinoids interact, inducing a variety of physiological and psychological effects.
Westley Cruces, Tesfay T. Tesfatsion, Giovanni A. Ramirez, Maite L. Docampo-Palacios, Arianna C. Collins, Kyle P. Ray, Prakash G. Jagtap   +6 more
doaj   +1 more source

Transporter‑mediated drug‑drug interactions involving poly (ADP‑ribose) polymerase inhibitors (Review). [PDF]

Oncol Lett, 2023
Zhao D, Long X, Wang J.
europepmc   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, EarlyView.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Peripheral Neuropathy Potentially Associated to Poly (ADP-Ribose) Polymerase Inhibitors: An Analysis of the Eudravigilance Database. [PDF]

Curr Oncol, 2023
Jesus M, Cabral A, Monteiro C, Duarte AP, Morgado M.   +4 more
europepmc   +1 more source